These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28859017)

  • 21. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(1):13-5. PubMed ID: 21228763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pertussis vaccine effectiveness following country-wide implementation of a hexavalent acellular pertussis immunization schedule in infants and children in Panama.
    Calvo AE; Tristán Urrutia AG; Vargas-Zambrano JC; López Castillo H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2389577. PubMed ID: 39164002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pertussis in infants under one year old: risk markers and vaccination status--a case-control study.
    Zamir CS; Dahan DB; Shoob H
    Vaccine; 2015 Apr; 33(17):2073-8. PubMed ID: 25728322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study.
    Maertens K; Caboré RN; Huygen K; Hens N; Van Damme P; Leuridan E
    Vaccine; 2016 Jan; 34(1):142-50. PubMed ID: 26592142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.
    Maertens K; Caboré RN; Huygen K; Vermeiren S; Hens N; Van Damme P; Leuridan E
    Vaccine; 2016 Jun; 34(31):3613-9. PubMed ID: 27142328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
    Bronson-Lowe D; Anderson SM
    Arch Pediatr Adolesc Med; 2009 May; 163(5):417-21. PubMed ID: 19414686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
    Scott LJ
    BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale for use of Tdap booster vaccines for adolescent immunization: overview of efficacy, safety, and clinical use.
    Hitchcock WP
    Clin Pediatr (Phila); 2006 Nov; 45(9):785-94. PubMed ID: 17041165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Waning Tdap Effectiveness in Adolescents.
    Klein NP; Bartlett J; Fireman B; Baxter R
    Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
    Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
    Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections.
    Khodr ZG; Bukowinski AT; Gumbs GR; Conlin AMS
    Vaccine; 2017 Oct; 35(42):5603-5610. PubMed ID: 28916245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do we need to boost pertussis immunization within the existing UK vaccination schedule?
    Beard SM; Finn A
    J Public Health Med; 2000 Sep; 22(3):349-56. PubMed ID: 11077909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
    Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
    Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimates of pertussis vaccine effectiveness in United States air force pediatric dependents.
    Wolff G; Bell M; Escobar J; Ruiz S
    Vaccine; 2015 Jun; 33(28):3228-33. PubMed ID: 25957071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future.
    Halperin SA
    J Pediatr; 2006 Nov; 149(5):589-91. PubMed ID: 17095321
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.